Summary Abdi Ibrahim Ilac Sanayi ve Ticaret AS (Abdi Ibrahim) is a pharmaceutical company which develops, manufactures, and markets original and generic prescription and non-prescription pharmaceutical products.Abdi Ibrahim’s product portfolio includes antianemic drugs, antibacterial or antiviral drugs, cardiovascular system drugs, dermatologic products, endocrine and metabolism products, gastrointestinal agents, antihypertensive and antianginal drugs, nonsteroidal anti-inflammatory (NSAI) drugs, myorelaxants, ophthalmic agents, respiratory system and urogenital system medications, vitamins and minerals.
The company established various joint investments and licensing agreements with leading pharmaceutical companies for the development and commercialization of its product portfolio.It markets and distributes its medications across Europe, CIS and Balkans, Middle East and North Africa, and Far East and Sub Saharan Africa.
It manages a manufacturing facility, a logistics center, and a research and development center in Esenyurt, Istanbul.The company has operations in Algeria, Kazakhstan, Azerbaijan, Georgia and Iraq.
Abdi Ibrahim is headquartered in Istanbul, Turkey.
Abdi Ibrahim Ilac Sanayi ve Ticaret AS - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The vaccines market was valued at US$ 39,128.3 million in 2019 and is projected to reach US$ 64,538.4 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.The major driving factors are rising prevalence of infectious diseases, growing focus on immunization programs, and increasing support for vaccine development are...
Retinopathy Of Prematurity - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Pipeline Review, H2 2020, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape. Retinopathy of prematurity...
Glomerulonephritis - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H2 2020, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape. Glomerulonephritis...
214 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for Anti-Tumor Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
Global Immunology Partnering 2014 to 2020 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Immunology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Immunology partnering...
Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Colorectal Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Colorectal Cancer Diagnostic Tests pipeline products...
The Global Molecular Diagnostics Partnering Terms and Agreements 2014-2020 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This...
The Global Biomarker Partnering Terms and Agreements 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in biomarker partnering deals Biomarker...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.